Drug manufacturer Glenmark Pharma is expected to report a growth of 11% year-on-year in its profit after tax of Rs 127 crore for the fourth quarter of FY12 (as per IFRS), according to CNBC-TV18.

See strong performance by pharma in Mar quarter: KR Choksey

According to the report on earnings preview for the quarter ended March 2012, KR Choksey expects the pharma sector will show strong performance in the domestic pharmaceuticals market mainly due to recovery in Indian pharma market.

Q3 earnings: Nirmal Bang reviews Glenmark, Divi's results

In an interview to CNBC-TV18, Praful Borah of Nirmal Bang Institutional Equities speak about Glenmark, Divi's results and gives his outlook going forward.

Glenmark Q3 PAT seen up 89% at Rs 106 cr QoQ

Glenmark Pharma is expected to report a profit after tax of Rs 106 crore in the third quarter of FY12, rising 89% as compared to Rs 56 crore in previous quarter.

Pharma Q3: New launches, generic drug demand to aid growth

Pharmaceutical companies are expected to report healthy 15-25% year-on-year revenue growth in the third quarter, helped by new launches especially in the US and strong demand for generic drugs.

Pharma stocks results preview for Q3FY12: KRChoksey

KRChoksey has come with its December quarterly earning estimates for Pharma sector. According to the research firm, Q3FY12 is expected to be a strong quarter in terms of top-line growth mainly due to improved performance in the Indian pharmaceutical market, launch of limited competitive products in the US market & rupee depreciation.

Pharmaceutical results preview for Q3FY12: Emkay

Emkay Global Financial Services has come with its December quarterly earning estimates for pharmaceutical sector. According to the research firm the sector is expected to report a growth of 18% YoY (5% QoQ) in revenues partly driven by Rupee depreciation which is likely to be 4-5% of the overall growth.

Q2 report card: Pharma sector posts encouraging numbers

After a sluggish first quarter, pharma universe reported some encouraging numbers in the second quarter. This is with some support from stable growth in certain geographies but inflationary pressures taking a test on the other hand report CNBC-TV18's Archana Shukla.

Glenmark Sept qtr PAT seen down 8% at Rs 102 cr: KR Choksey

KR Choksey has come out with its earning estimates on Pharma sector for the quarter ended September 2011. According to the research firm, Glenmark Pharma September quarter net sales are expected to go up by 11% at Rs 819 crore, year-on-year, (YoY) basis.

Q1 results review: Elara Capital's call on Glenmark Pharma

Glenmark Pharma has reported a rise of 23.5% (YoY) in its first quarter net profit. In an interview with CNBC-TV18, Surajit Pal, pharma analyst, Elara Capital said, the top-line is very much in line, just 3% below his expectations. “Bottom-line margin has increased quite significantly, much above our expectation,” he added.

Glenmark Q1 PAT seen up 13.7% to Rs 177 cr

Glenmark Pharma is expected to report a rise of 13.7% in its first quarter FY12 profit after tax to Rs 177 crore against Rs 155 crore in same quarter the previous year.

Mid-sized pharma margins to crimp despite sales

Mid-sized Indian drugmakers are expected to post steady to strong revenue growth in April-June, riding healthy domestic and overseas demand, but higher would crimp margins.

Glenmark Pharma Jun qtr PAT seen Rs 79cr: KRChoksey

KRChoksey has come out with its earning estimates on pharma sector for the quarter ended June 2011. According to the research firm, Glenmark Pharma June quarter sales are expected to go up by 26% at Rs 761 crore, year-on-year, (YoY) basis.

Glenmark Jun qtr PAT seen up at Rs 157 cr: PINC

PINC Research has come out with its earning estimates on pharma sector for the quarter ended June 2011. According to the research firm, Glenmark June quarter net revenues are expected to go up by 17.5% at Rs 801.1 crore, year-on-year, (YoY) basis.

Glenmark Pharma sees its India business growing at 23-24%

Glenn Saldanha, managing director and CEO of Glenmark Pharmaceuticals, in an interview with CNBC-TV18's Udayan Mukherjee and Mitali Mukherjee, said that its business in India is growing at 23-24%, while its business in US is expected to grow 25% in FY12.

Glenmark Pharma Q4 PAT seen up 1.2% to Rs 104cr

Glenmark Pharma is to announce its fourth quarter results. According to CNBC-TV18’s estimates, the company’s Q4FY11 revenues are seen up 12% to Rs 795 crore versus Rs 712.5 crore, year-on-year, YoY.

Glenmark Pharma Mar qtr PAT seen down at Rs 98.8 cr: MOST

Motilal Oswal has come out with its earning estimates on Pharmaceuticals sector for the quarter ended March 2011. According to the research firm, Glenmark Pharma March quarter sales are expected to go up by 7% at Rs 759 crore, year-on-year, (YoY) basis.

Glenmark Pharma March qtr PAT seen at Rs 98cr: KRChoksey

KRChoksey has come out with its earning estimates on pharma sector for the quarter ended March 2011. According to the research firm, Glenmark Pharma March quarter sales are expected to go up by 10% at Rs 781 crore, year-on-year, (YoY) basis.

Glenmark Dec qtr PAT seen up 6.6% at Rs 111cr: Emkay

Emkay Global Financial Services has come out with its earning estimates on pharma sector for the quarter ended December 2010. According to the research firm, Glenmark December quarter sales are expected to go up by 19.8% to Rs 770.4 crore, Year-on-Year, (Y-o-Y) basis.

Glenmark Dec qtr PAT seen up 30% at Rs 105cr: KRChoksey

KRChoksey has come out with its earning estimates on pharma sector for the quarter ended December 2010. According to the research firm, Glenmark Pharma December quarter sales are expected to go up by 30% to Rs 781 crore, Year-on-Year, (Y-o-Y) basis.